Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

which is currently given via intravenous (i.v.) infusion. As a line extension, it expands the blockbuster drug franchise and extends the patent protection for Herceptin—a strategy Roche could ...

[54] Trastuzumab should not be administered as an i.v. push or bolus infusion. Trastuzumab is available as a preservative- free lyophilized powder for i.v. injection. The drug is formulated in ...

The primary analysis of KATHERINE, a phase 3, open-label trial, showed that the risk of invasive breast cancer or death was 50% lower with adjuvant trastuzumab emtansine (T-DM1) than with ...

Enhertu (fam-trastuzumab deruxtecan-nxki) is a brand-name drug prescribed for certain cancers. Enhertu comes as an intravenous (IV) infusion given by a healthcare professional. The dosage can vary ...

Alteogen will receive an upfront payment of $20 million, with another $280 million on offer from Daiichi Sankyo if the new formulation of Enhertu (trastuzumab deruxtecan) makes it to market and ...

The MARGOT/TBCRC052 trial didn't show improvement in pathologic complete response rates with margetuximab for early-stage HER2-positive breast cancer.